Evinacumab for Homozygous Familial Hypercholesterolemia
Evinacumab for Homozygous Familial Hypercholesterolemia
About this item
Full title
Author / Creator
ELIPSE HoFH Investigators , Raal, Frederick J , Rosenson, Robert S , Reeskamp, Laurens F , Hovingh, G. Kees , Kastelein, John J.P , Rubba, Paolo , Ali, Shazia , Banerjee, Poulabi , Chan, Kuo-Chen , Gipe, Daniel A , Khilla, Nagwa , Pordy, Robert , Weinreich, David M , Yancopoulos, George D , Zhang, Yi and Gaudet, Daniel
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Among 65 patients with homozygous familial hypercholesterolemia, the use of evinacumab, a monoclonal antibody against ANGPTL3, resulted in a reduction from baseline in the LDL cholesterol level, as compared with a small increase with placebo, for a between-group difference of 49.0 percentage points at 24 weeks.
Alternative Titles
Full title
Evinacumab for Homozygous Familial Hypercholesterolemia
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2435558805
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2435558805
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2004215
